Evaluation of sampling spacing in pharmacokinetic studies using six sigma method

被引:0
作者
Grabowski, Tomasz [1 ]
Raczynska-Pawelec, Anna [2 ]
Starosciak, Marcin [2 ]
Jaroszewski, Jerzy Jan [3 ]
机构
[1] Polpharma Biol, PL-80172 Gdansk, Poland
[2] Polfa Warszawa S A, PL-01207 Warsaw, Poland
[3] Univ Warmia & Mazury, Dept Pharmacol & Toxicol, Fac Vet Med, PL-10718 Olsztyn, Poland
关键词
Six sigma; Sampling; Quality; Pharmacokinetics; QUALITY INDICATORS;
D O I
10.1007/s10928-014-9361-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Key elements of pharmacokinetics (PK) studies include both, the number of sampling points (NSP) as well as the spacing between the sampling points (SSP). Optimization of the SSP is discussed in guidelines of all key regulatory agencies (RA). Those however, provide only very general rules on how to properly distribute the NSPs in proposed PK studies. Here we demonstrate that the six sigma (SX) method can be effectively used to assess the quality of SSPs. We have tested a modified SX method analyzing 466 PK profiles from 16 studies including a total of 368 healthy volunteers. Non-compartmental modeling was used to estimate PK parameters. The arithmetic means of minimum and maximum values of SX obtained for each subject in all studies were 1.97 and 3.83, respectively. The method described here allows comparing quality of studies performed at different centers, even if they cover different chemical entities. We propose that the SX values can be used to assess quality of PK studies, what is consistent with recommendations of the RAs.
引用
收藏
页码:251 / 260
页数:10
相关论文
共 22 条
  • [1] [Anonymous], GUID DEV MED PROD TR
  • [2] [Anonymous], 2003, Guidance for Industry: Q1A(R2) Stability Testing of New Drug Substances and Products, P1
  • [3] [Anonymous], 2005, Potential timber damage due to hurricane Katrina in Mississippi, Alabama, and Louisiana- September 22, 2005, P1
  • [4] [Anonymous], 2000, Guidance for the submission of research and marketing applications for permanent pacemaker leads and for pacemaker lead adaptor 510(k) submissions, P1
  • [5] Quality indicators and specifications for key analytical-extranalytical processes in the clinical laboratory. Five years' experience using the Six Sigma concept
    Antonia Llopis, Ma
    Trujillo, Gloria
    Isabel Llovet, Ma
    Tarres, Ester
    Ibarz, Merce
    Biosca, Carme
    Ruiz, Rosa
    Alsina Kirchner, Ma Jesus
    Alvarez, Virtudes
    Busquets, Gloria
    Vicenta Domenech, Ma
    Figueres, Carme
    Minchinela, Joana
    Ma Pastor, Rosa
    Perich, Carmen
    Ricos, Carmen
    Sansalvador, Mireia
    Simon Palmada, Margarita
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 (03) : 463 - 470
  • [6] Chopra Vikram, 2012, PDA J Pharm Sci Technol, V66, P98, DOI 10.5731/pdajpst.2012.00807
  • [7] Christian DR, 2009, IMPLEMENTING QUALITY, P1
  • [8] A six-sigma approach to stability testing
    De Vore, Karl
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 47 (02) : 413 - 421
  • [9] Using Six Sigma to improve once daily gentamicin dosing and therapeutic drug monitoring performance
    Egan, Sean
    Murphy, Philip G.
    Fennell, Jerome P.
    Kelly, Sinead
    Hickey, Mary
    McLean, Carolyn
    Pate, Muriel
    Kirke, Ciara
    Whiriskey, Annette
    Wall, Niall
    McCullagh, Eddie
    Murphy, Joan
    Delaney, Tim
    [J]. BMJ QUALITY & SAFETY, 2012, 21 (12) : 1042 - 1051
  • [10] Elder B.L., 2008, Clinical Microbiology Newsletter, V30, P143, DOI DOI 10.1016/J.CLINMICNEWS.2008.09.001